The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with Myeloma

References

• Dutton R. W., Falkoff R., Hirst J. A., Hoffman M., Kappler J., Kettman J. R., Lesley J. F., Van D. Is there evidence for a nonantigen specific diffusible chemical mediator from the thymus cell in the initiation of the immune response?. Progress in Immunology 1971; 1: 355–70
   Google Scholar
• Kishimoto T., Ishizaka K. Regulation of antibody responses in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. Journal of Immunology 1973; 111: 1194–1205
   PubMed Web of Science ®Google Scholar
• Muraguchi A., Kishimoto T., Miki Y., Kuritani T., Kaieda T., Yoshizaki K., Yamamura Y. T cell replacing factor (TRF)-induced IgG secretion in human B blastoid cell line and demonstration of acceptors for TRF. Journal of Immunology 1981; 127: 412–6
   PubMed Web of Science ®Google Scholar
• Okada M., Sakaguchi N., Yoshimura N., Hara H., Shimizu K., Yoshida N., Yoshizaki K., Kishimoto S., Yamamura Y., Kishimoto T. B-cell growth factor (BCGF) and B cell differentiation factor from human T hybridomas: Two distinct kinds of BCGFs and their synergism in B cell proliferation. Journal of Experimental Medicine 1989; 157: 583–90
   Web of Science ®Google Scholar
• Kishimoto T. The biology of Interleukin-6. Blood 1989; 74: 1–10
   PubMed Web of Science ®Google Scholar
• Harada N., Kikuchi Y., Taminaga A., Takaki S., Takatsu K. BCGF II activity on activated B cells of a purified murine T cell replacing factor (TRF) from a T cell hybridoma (B151K12). Journal of Immunology 1985; 134: 3944–51
   PubMed Web of Science ®Google Scholar
• Kinashi T., Harada N., Severinson E., Tanabe R., Sideras P., Konishi M., Azuma C., Tominaga A., Bergstedt-Lindquist S., Takahashi M., Matsuda F., Yaoita Y., Takatsu K., Honjo T. Cloning of complementary DNA coding T-cell replacing factor and identity with B-cell growth factor II. Nature 1986; 324: 70–3
   PubMed Web of Science ®Google Scholar
• Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and Interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. Journal of Experimental Medicine 1989; 170: 613–8
   PubMed Web of Science ®Google Scholar
• Van Damme J. G., Opdenakker G., Simpson R. J., Rubira M. R., Cayphas S., Vink A., Billau A., Van Snick J. Identification of the human 26kD protein, interferon B2 (IFN-B2) as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. Journal of Experimental Medicine 1987; 165: 914–20
   PubMed Web of Science ®Google Scholar
• Asaoku H., Kawano M., Iwato K., Tanabe O., Tanaka H., Hirano T., Kishimoto T., Kuramoto A. Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. Blood 1988; 72: 429–32
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human myelomas. Nature 1988; 332: 83–4
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Jourdan M., Content J., Houssaiu F., Aarden L., Piechaczyck M., Bataille R. A paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–26
   PubMed Web of Science ®Google Scholar
• Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., Miyazaki J., Yamamura Y., Hirano T., Kishimoto T. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proceedings of the National Academy of Science 1989; 86: 7547–51
   PubMed Web of Science ®Google Scholar
• Nijstein M. W. N., De Groot E. R., Ten Duis H. J., Klansen H. J., Aarden L. A. Serum levels of interleukin-6 and acute phase responses. Lancet 1987; i: 921
   Google Scholar
• Hack C. E., De Groot E. R., Felt-Bersma R. J., Nuijens J. H., Strack van Schijndel R. J., Eerenberg-Belmer A. J., Thijs L. S., Aarden L. A. Increased plasma levels of interleukin 6 in sepsis. Blood 1989; 74: 1704–10
   PubMed Web of Science ®Google Scholar
• Deviere J., Content J., Denys C., Vandenbusche P., Schandene L., Wybran J., Dupont E. High interleukin 6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokine production. Clinical and Experimental Immunology 1989; 77: 221–5
   PubMed Web of Science ®Google Scholar
• Kern P., Heimmer C. J., Van Damme J., Gruss H. J., Dietrich M. Elevated tumour necrosis factor alpha and interleukin 6 serum levels as markers for complicated Plasmodium falciparnum malaria. American Journal of Medicine 1989; 87: 139–43
   PubMed Web of Science ®Google Scholar
• Swaak J. Interleukin 6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatology International 1989; 8: 263–8
   PubMed Web of Science ®Google Scholar
• Shenkin A., Fraser W. D., Semies J., Winstanley F. P., McCartney A. C., Burns H. J., Van Damme J. The serum interleukin 6 response to elective surgery. Lymphokine Research 1989; 8: 123–7
   PubMedGoogle Scholar
• Van Oers M. H. J., Van der Heyden A. A., Aarden L. A. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clinical and Experimental Immunology 1988; 71: 314–9
   PubMed Web of Science ®Google Scholar
• Houssaiu F. A., Bukasa K., Sindic C. J. M., Van Damme J., Van Snick J. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clinical and Experimental Immunology 1988; 71: 320–3
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X. G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation 1989; 84: 2008–11
   PubMed Web of Science ®Google Scholar
• Chronic-Leukaemia-Myeloma Task Force. Proposed guidelines for clinical studies. Cancer Chemotherapy Reviews 1973; 4: 145–58
   Google Scholar
• Kikutani H., Taga T., Akira S., Kishi H., Miki Y., Saiki O., Yamamura Y., Kishimoto T. Effect of B cell differentiation factor (BCDF) on biosynthesis and secretion of immunoglobulin molecules in human B cell lines. Journal of Immunology 1985; 134: 990–5
   PubMed Web of Science ®Google Scholar
• Gauldie J., Richards C., Harnish D., Lansdrop P., Baumann H. Interferon B2/Bcell stimulating factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Science 1987; 84: 7251–5
   PubMed Web of Science ®Google Scholar
• Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., Tanabe O., Kuramato A. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 1989; 73: 2145–8
   PubMed Web of Science ®Google Scholar
• James K. Interactions between cytokines and alpha-2-macroglobulin. Immunology Today 1990; 11: 163–6
   PubMedGoogle Scholar
• Brown R. D., Ioannidis R. A., Joshua D. E., Kronenberg H. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Australian and New Zealand Journal of Medicine 1989; 19: 226–32
   PubMedGoogle Scholar